Andrea Necchi

Andrea Necchi
申请预约
专科:
肿瘤科 泌尿生殖系统肿瘤科 泌尿科 成人泌尿科
+1
职业:
肿瘤科医生
医疗机构:
临床肿瘤科 @ 圣拉斐尔科学研究医院
语言:
EN
IT
申请预约

个人简介

Andrea Necchi教授是一名专攻泌尿系统恶性肿瘤治疗的肿瘤内科医生，在米兰圣拉斐尔科学研究医院担任泌尿生殖系统肿瘤内科负责人，还是圣拉斐尔生命健康大学（UniSR）的肿瘤学副教授。

Necchi教授先后在米兰大学获得医学学位和肿瘤内科博士后专业学位。Necchi教授自作为医学生接受临床培训以来一直就职于意大利国家癌症研究所基金会（位于意大利米兰），2020年11月开始在圣拉斐尔科学研究医院执业。

Necchi教授主要从事泌尿生殖系统恶性肿瘤的治疗工作。其研究团队专注于泌尿系统恶性肿瘤的全部领域，主要致力于新试验性治疗的全阶段临床试验研发。Necchi教授近期的工作重点是制定在可手术治疗疾病的早期引入新疗法联合根治性手术的围手术期策略。

您需要预约吗？

联系我们，我们将为您妥善安排。
申请预约

出版物

最新出版物

Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Urothelial Bladder Carcinoma (PURE-01): An Open-Label, Single-Arm, Phase II Study.
J Clin Oncol. 2018 Dec 1;36(34):3353-3360.
Necchi A, Anichini A, Raggi D, et al.
Impact of Molecular Subtyping and Immune In ltration on Pathological Response and Outcome Following Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer
Eur Urol. 2020 Jun;77(6):701-710.
Necchi A, Raggi D, Gallina A, et al.
Does the administration of preoperative pembrolizumab lead to sustained remission post-cystectomy?
First survival outcomes from the PURE-01 study. Ann Oncol. 2020 Dec;31(12):1755-1763.
Bandini M, Gibb EA, Gallina A, et al.
Erda tinib in Locally Advanced or Metastatic Urothelial Carcinoma
N Engl J Med. 2019 Jul 25;381(4):338-348.
Loriot Y, Necchi A, Park SH, et al.
Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial
Lancet Oncol 2012;8:810-16.
Necchi A, Mariani, Zaffaroni N, et al.
Proof of activity of anti-EGFR targeted therapy for relapsed squamous-cell carcinoma of the penis
J Clin Oncol 2011;29:2178-84.
Necchi A, Nicolai N, Colecchia C et al.
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
N Engl J Med. 2017 Mar 16;376(11):1015-1026.
Bellmunt J, de Wit R, Vaughn DJ, et al.
Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatinineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trial. Lancet Oncol
2021 Jun;22(6):872-882.
Yu EY, Petrylak DP, O'Donnell PH, et al.
Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial
Lancet Oncol. 2020 Dec;21(12):1574-1588.
Powles T, van der Heijden MS, Castellano D, et al.
Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial
Lancet Oncol. 2017 Mar;18(3):312-322.
Sharma P, Retz M, Siefker-Radtke A, et al.
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
Lancet. 2016 May 7;387(10031):1909-20.
Rosenberg JE, Hoffman-Censits J, Powles T, et al.
Atezolizumab as  rst-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
Lancet. 2017 Jan 7;389(10064):67-76.
Balar AV, Galsky MD, Rosenberg JE, et al.
Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial
Lancet. 2017 Nov 18;390(10109):2266-2277.
Petrylak DP, de Wit R, Chi KN, et al.
Contrasting genomic pro les from metastatic sites, primary tumors, and liquid biopsies of advanced prostate cancer
Cancer. 2021 Aug 11. doi: 10.1002/cncr.33865. Online ahead of print.
Necchi A, Cucchiara V, Grivas P, et al.
Molecular Characterization of Residual Bladder Cancer after Neoadjuvant Pembrolizumabur
Eur Urol. 2021 Aug;80(2):149-159.
Necchi A, de Jong JJ, Raggi D, et al.

您需要预约吗？

联系我们，我们将为您妥善安排。
申请预约